



IgA, IgG and Cell-Mediated Immunity: A Comprehensive Understanding of Effective Respiratory Syncytial Virus (RSV) Vaccines

Guest Editor:

Dr. Cunbao Liu

Institute of Medical Biology,
Chinese Academy of Medical
Sciences and Peking Union
Medical College, Kunming
650118, China

Deadline for manuscript
submissions:

closed (30 September 2023)

Message from the Guest Editor

Dear Colleagues,

Considering the complexity of RSV vaccination targets, which include infants, pregnant women and the elderly, we think it is time to summarize the experiences on the development of RSV vaccines based on non-inactivated technologies, in particular, those which can avoid immunopathology in infants, and those which may induce a high rate of protection and long-lasting efficacy in the elderly. In this Special Issue, contributions in the form of original research or reviews, including, but not limited to, the following topics are welcome: (i) basic research on RSV invasion and immunopathology; (ii) vaccine immunization strategies; (iii) vaccine antigen prefusion protein design; (iv) adjuvant effects to elevate vaccine efficacy and to lower the risk of immunopathology; and (v) strategies to avoid antibody decline and prolong vaccine efficacy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com